Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-30
2006-05-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S404000
Reexamination Certificate
active
07053117
ABSTRACT:
The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the general Formula I:wherein R1–R5, A, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 4698345 (1987-10-01), Dicker et al.
patent: 5281619 (1994-01-01), Dell et al.
patent: 5284868 (1994-02-01), Dell et al.
patent: 5434160 (1995-07-01), Dell et al.
patent: 5514706 (1996-05-01), Ambler et al.
patent: 5571818 (1996-11-01), Williams
patent: 5574034 (1996-11-01), Williams
patent: 5576325 (1996-11-01), Williams
patent: 5624953 (1997-04-01), Ambler et al.
patent: 5637589 (1997-06-01), Lee et al.
patent: 5726204 (1998-03-01), Lee et al.
patent: 5847165 (1998-12-01), Lee et al.
patent: 6160010 (2000-12-01), Uckun et al.
patent: 6221900 (2001-04-01), Uckun et al.
patent: 6258824 (2001-07-01), Yang
patent: 6294575 (2001-09-01), Uckun et al.
patent: 6303652 (2001-10-01), Uckun et al.
patent: 6365626 (2002-04-01), Uckun et al.
patent: 6388092 (2002-05-01), Yang
patent: 2002/0076733 (2002-06-01), Kasibhatla et al.
patent: 0 537 949 (1993-04-01), None
patent: 0 599 514 (1994-06-01), None
patent: 0 618 206 (1994-10-01), None
patent: 0 619 314 (1994-10-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 98/24427 (1998-06-01), None
patent: WO 99/54286 (1999-10-01), None
patent: WO 99/54286 (1999-10-01), None
patent: WO 00/04901 (2000-02-01), None
patent: WO 01/34591 (2001-05-01), None
patent: WO 03/096982 (2003-11-01), None
patent: WO 03/097806 (2003-11-01), None
Al-Mousawi et al., CAPLUS Abstract 131: 199593, 1999.
Klokol et al., CAPLUS Abstract 108:5822, 1988.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Wachlin et al., IL-1beta, IFN-gamma and TNF-alpha increase vulnerability of pancreatic beta cells to autoimmune destruction, Journal of Autoimmunity, 20, pp. 303-312, 2003.
Elgert, Immunology—Understanding the Immune System, pp. 315-331, 1996.
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21stCentury, Eur. J. Surg. Suppl. 582: 90-98, 1998.
Shevach, Animal Models for Autoimmune and Inflammatory Disease, Current Protocols in Immunology, Suppl. 52, 15.0.1-15.0.6, 2002.
Singh et al., Immune Therapy in Inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, pp. 1558-1569, 2001.
Bremner et al., Therapy of Crohn's Disease in childhood, Expert Opin. Pharmacother. 3(7):809-825, 2002.
Thornberry, N. A., et al., “A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B. Functional Relationships Established for Key Mediators of Apoptosis,”J. Biol. Chem. 272:17907-17911, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Immunologists (1999).
Birch, K.A., et al., “LY290181, an Inhibitor oF Diabetes-Induced Vascular Dysfunction, Blocks Protein Kinase C-Stimulated Transcriptional Activation Through Inhibition of Transcription Factor Binding to a Phorbol Response Element,”Diabetes45 :642-650, American Diabetes Association (1996).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116: 557-565, The American Gastroenterological Association (1999).
Coven, T. R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Munksgaard (1999).
Ellis, R.E., et al., “Mechanisms and Functions of Cell Death,”Ann. Rev. Cell Biol. 7:663-698, Annual Reviews, Inc. (1991).
Friesen, C., et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med. 2:574-577, Nature Publishing Co. (1996).
Greenwald, R.B., et al., “Drug Delivery Systems Employing 1, 4- or 1,6- Elimination: Poly (ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem. 42 :3657-3667, American Chemical Society (1999).
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290 : 240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133 : 629-633, Mosby, Inc. (1998).
Leu, Y. -L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT) ,”J. Med. Chem. 42:3623-3628, American Chemical Society (1999).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review) ,”Int. J. Mol. Med. 1: 475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases) ,”Blood 90:3118-3129, W.B. Saunders Co. (1997).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48: 5-21, Birkhäuser Verlag (1999).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (1999).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Internal Med. 237:529-536, Blackwell Science Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (1999).
Panda, D., et al., “Suppression of Microtubule Dynamics by LY290181: A Potential Mechanism for Its Antiproliferative Action,”J. Biol. Chem. 272: 7681-7687, The American Society for Biochemistry and Molecular Biology, Inc. (1997).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61 : 375-380, The Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and BAX-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, National Research Council of Canada (1997).
Smith, C.W., “The Anti-rheumatic Potential of a Series of 2, 4-Di-substituted-4H-naphtho [1,2-b] pyran-3-carbonitriles,”Bioorg. Med. Chem. Lett. 5:2783-2788, Elsevier Science Ltd. (1995).
Thornberry, N.A., “The caspase family of cysteine proteases,”Brit. Med. Bull. 53:478-490, Oxford University Press (1997).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chem. Biol. 5:R97-R103, Current Biology Ltd. (1998).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations,”J. Clin. Invest. 103:355-363, The American Society for Clinical Investigation (1999).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA) ,”Clin. Exp. Immunol. 114 : 119-128, Blackwell Science (1998).
Wood, D.L., “Inhibition of Mitosis and Microtubule Function through Direct Tubulin Binding by a Novel Antiproliferative Naphthopyran LY290181,”Mol. Pharmacol. 52:437-444,
Cytovia, Inc.
Rao Deepak
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Substituted 4H-chromenes and analogs as activators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4H-chromenes and analogs as activators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4H-chromenes and analogs as activators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3583372